Watch out Bristol Myers, Merck is right on your heels with more positive Keytruda data to take to the FDA
Merck announced positive Phase III results to back yet another indication for cash cow Keytruda — this time as a first-line esophageal cancer treatment in combination with chemotherapy.
Keytruda already has the FDA OK as a second-line monotherapy for PD-L1-positive patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus. But Merck is still pushing for first-line approval as a therapy for the difficult-to-treat cancer, and it met primary endpoints in a Phase III trial.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters